SC7: Introduction to Bispecific Antibodies: Design, Formats and Applications
SUNDAY, August 30 | 2:30 – 4:30 PM
ABOUT THIS COURSE:
Bispecific antibodies are a rapidly growing therapeutic modality that allow simultaneous targeting of disease mediators. This course serves as an introduction to bispecific antibodies by highlighting the history, design of different bispecific formats, and therapeutic applications of multiple clinical-stage bispecific antibodies. The course will also contrast the development process of a bispecific program with that of a traditional monospecific antibody and underscore the critical attributes specific to bispecific antibody development.
WHAT YOU WILL LEARN:
- Why do we need bispecifics and the history of bispecific antibodies
- How to design and generate bispecific antibodies in different formats
- Applications of bispecific antibodies in multiple disease indications
- How to select the appropriate bispecific antibody format for your therapeutic application
COURSE AGENDA:
2:30 pm Introduction: History, Design and Formats of Bispecific Antibodies
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
This module will highlight the history and need for bispecific antibodies and provide an overview of the design of multiple formats. We will also discuss how to select the appropriate bispecific format(s) for various therapeutic applications
3:10 Refreshment Break
3:40 Applications of Bispecific Antibodies
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
This module will discuss and review bispecific antibodies that are either approved or in late stage development for therapeutic applications
4:00 Development of Bispecific Antibodies
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
This module will underscore the salient features distinguishing a bispecific development program from a traditional monospecific antibody program
4:30 Close of Course
INSTRUCTOR BIOGRAPHY:
Nimish Gera, PhD, Head, Biologics, Mythic Therapeutics
Nimish Gera is the Head of Biologics at Mythic Therapeutics, leading multiple programs to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over ten years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.